Drugs / CART33 cells
CART33 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01864902 | Apr 2013 → Apr 2016 | acute myeloid leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART33 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01864902 ↗ |
| Known as | anti-CD33 CAR T cells | “Biological: anti-CD33 CAR T cells” NCT01864902 ↗ |
| Known as | anti-CD33 CART | “Biological: anti-CD33 CART” NCT01864902 ↗ |
| Known as | CART-33 | “We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric antigen receptor-modified T cells (CART-33) for the treatment of refractory acute...” PMID 25174587 ↗ Sep 2014 |
| Action | Deplete | “leukemia cell killing by CART-33 cells” NCT01864902 ↗ |
| Modality | Cell therapy | “genetically modified lymphocyte therapy” NCT01864902 ↗ |